© Simply 3 Capital
© Simply 3 Capital
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology
We will share insight into the share of Eris Lifesciences.
Eris Lifesciences has recently seen its Chairperson and managing Director Mr. Amit Bakshi buying shares from open market. He already holds close to 40% of shares in the company and he ahs been buying shares from December 2022 when the market price has been hovering around 660.
The current price of the stock is 585.
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology.
The current Market Cap of the company is around 7900 crores.
Among the major institutional investor the shares of the company is held with UTI , Franklin, Aditya Birla and Kuwait Investment Authority.
The current PE of the company is 20 whereas its median PE has been 24 .The current Price to book Value has been 3.8 with its long term average median P/BV of 5.6.
# Disclaimer- Please note that this Blog has been created with the primary goal of providing its readers with up-to-date information on the Financial Markets. Its purpose is to share knowledge about Financial products, insights from Market experts, recent developments in the financial industry, and business-related information about companies. It is important to emphasize that the Blog should not be interpreted as providing any form of advice. It does not intend to recommend or endorse the buying, selling, or trading of any financial product. The Blog is purely educational in nature.